Antitumor necrosis factor therapy for Inflammatory Bowel Disease: A review of agents, pharmacology, clinical results, and safety

Inflammatory Bowel Diseases

Volumn 5, Issue 2, 1999, Pages 119-133

  Sandborn, William J ^a   Hanauer, Stephen B ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antibody Crohn's disease; Antitumor necrosis factor; CDP571; Etanercept; Infliximab; Rheumatoid arthritis

Indexed keywords

IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT PROTEIN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CROHN DISEASE; HUMAN; IMMUNOLOGY; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033125226     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-199905000-00008     Document Type: Review

References (81)

1. Carroll MC, Katzman P, Alicot EM, Koller BH, Gerathy DE, Orr HT, Strominger JL, Spies T. Linkage map of the human histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci USA 1987;84:8535-9.
2. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985;260:2345-54.
3. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987;262:6951-4.
4. Hohmann HP, Remy R, Brockhaus M, van Loon APGM. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 1989;264:14927-34.
5. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-31.
6. Pennica D, Kohr WJ, Fendly BM, Shire SJ, Raab HE, Borchardt PE. Characterization of a recombinant extracellular domain of the type I tumor necrosis factor receptor: evidence for tumor necrosis factor-α induced receptor aggregation. Biochemistry 1992;31: 1134-41.
7. Flier JS, Underbill LH. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
8. Lantz M, Gullberg U, Nilsson E, Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. Asoluble binding form of tumor necrosis factor receptor. J Clin Invest 1990;86: 1396-1402.
9. Kohno T, Brewer MT, Baker SL. A second tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990;87:8331-5.
10. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA. Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993;4:169-80.
11. Van Deventer SJH. Tumor necrosis factor and Crohn's disease. Gut 1997;40:443-8.
12. Eigler A, Sinha B, Hartman G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18:487-492.
13. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17.
14. Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-α is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:233-6.
15. Nielson OH, Brynskov J, Bendtzen K. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. Dan Med Bull 1993;40:247-9.
16. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
17. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993;46:757-60.
18. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
19. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 1992;33:1214-19.
20. Isaacs KL, Sartor RB, Haskill S. Cytokines messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103: 1587-95.
21. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Peppercorn MA, Strom TB. Tumor necrosis factor-alpha, interleukin-1B, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
22. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
23. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
24. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schrieber S, MacDermott RP, et al. Clin Exp Immunol 1993;94:174-81.
25. Noguchi M, Hiwatashi N, Lui Z, Toyota T. Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9.
26. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. A role for TNFα and mucosal T helper-1 cytokines in the pathogenesis of Crohn disease. J Immunol 1997; 159:6267-82.
27. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman TAJ, DeWoody KL, Schaible TF, Rutgeerts P, and the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
28. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA, Hawkey CJ. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-4.
29. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243-6.
30. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan A. Human anti-murine immunoglobin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
31. Adir JR. Engineering antibodies for therapy. Immunol Rev 1992; 130:5-40.
32. LoBluglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey HB, Sun L, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibodies in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
33. Trang JM. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Protein pharmacokinetic and metabolism. New York: Plenum Press, 1992:223-64.
34. Feldman M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997;64: 283-350.
35. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobblod SP, Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
36. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J. Construction and initial characterization of a house-human chimeric antibody. Mol Immunol 1993;30:1443-53.
37. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Daddona PE. The mouse/human chimeric monoclonal antibldy cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
38. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibldy cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7:251-9.
39. Kam L, Targan S. Infliximab and Crohn's disease. Clin Perspec Gastroenterol 1998;1:67-72.
40. Wagner C, Mace K, deWoody K, Zelinger D, Leone A, Schaible T, Shealy D. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn's disease patients. Digestion 1998; 59(suppl 3):124-5.
41. Hommes DW, van Dullemen HM, Levi M, van der Ende A, Woody J, Tytgat GNJ, van Deventer SJH. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-α antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 1997;27:269-77.
42. 2 in healthy humans and active Crohn's disease. Scand J Gastroenterol 1998;33:1094-8.
43. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nublein H, Woody J, Kalden JR, Manger B. In vivo blockade of TNF-α by infusion of a monoclonal TNF-α antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996;156:1646-53.
44. Paleolog EM, Hunt M, Elliott MJ, Feldman M, Maini RN, Woody JN. deactivation of vascular endothelium by monoclonal antitumor necrosis factor αantibody in rheumatoid arthritis. Arth Rheum 1996;39:1082-91.
45. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldman M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following antitumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36: 643-50.
46. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M. comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic repsonses. Immunology 1995;85:668-74.
47. Suitters AJ, Foulkes R, Opal SM, Palardy JE, Emtage JS, Rolfe M, Stephens S, Morgan A, Holt AR, Chaplin LC, Shaw NE, Nesbitt AM, Bodmer MW. Differential effect of isotype on efficacy of anti-tumor necrosis factor α chimeric antibodies in experimental septic shock. J Exp Med 1994;179:849-56.
48. Redl H, Schlag G, Paul E, Bahrami S, Buurman WA, Strieter RM, Kunkel SL, Davies J, Foulkes R. Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia. Am J Physiol 1996;271:R1193-8.
49. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
50. Jacobs CA, Beckmann MP, Mohler K, Maliszewski CT, Fanslow WC, Lynch DH. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 1993;34B:123-35.
51. Enbrel (etanercept). Prescribing Information. Physician's Desk Reference 1999.
52. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996;61:224-8.
53. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-45.
54. Remicade (infliximab). Prescribing Information. Physician's Desk Reference 1999.
55. Derx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tygat G, van Deventer S. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
56. Van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
57. McCabe RP, Woody J, van Deventer S, Targan SR, Mayer L, van Hogezard R, Rutgeerts P, Hanauer SB, Podolsky D, Elson CO. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996;110: A962.
58. Present D, Mayer L, van Deventer SJH, Rutgeerts P, Hanauer S, Targan SR, DeWoody K, Braakman T, Schaible T, and the cA2 Study Group. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1997;92:1746.
59. Van Dullemen HM, de Jong E, Slors F, Tytgat GNJ, van Deventer SJH. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2. Dis Colon Rectum 1998;41:98-102.
60. Rutgeerts P, D'Haens GD, van Deventer SJH, Present DH, Mayer L, Hanauer SB, Braakman TAJ, DeWoody KL, Schaible TF, Targan SR, and the Crohn's Disease cA2 Study Group. Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997;112:A1078.
61. Elliott MJ, Maini RN, Feldman M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bilj H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;12:1681-90.
62. Elliott MJ, Maini RN, Feldman M, Lonf-Fox A, Charles P, Bilj H, Woody JN. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
63. Elliott MJ, Maini RN, Feldman M, Kalden JR, Antoni C, Smolen JS, Leed B, Breedveld FC, Macfarlane JD, Bilj H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
64. Kavanaugh A, Cush J, St Clair E, et al. Anti-TNFα monoclonal antibody treatment of rheumatoid arthritis patients with active disease on methotrexate: results of a double-blind, placebo controlled multicenter trial. Arthritis Rheum 1996;39(Suppl):123.
65. Kavanaugh A, Cush J, St. Clair E, et al. Anti-TNFα monoclonal antibody treatment of rheumatoid arthritis patients with active disease on methotrexate: results of open label, repeated dose administration following a double-blind, placebo controlled. Arthritis Rheum 1996;39(Suppl):244.
66. Maini RN, Breeveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leed B, Elliott MJ, Woody JN, Schaible TF, Feldman M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;1552-63.
67. Lipsky P, St Clair W, Kavanaugh A, McCune W, Smolen J, Breedveld F, Furst D, Kalden J, Weissman M, Braakman T, Schaible T, Maini R. Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNFα antibody (infliximab) in patients with active disease on methotrexate. Arthritis Rheum 1998;41(Suppl):5364.
68. Moreland LW, Margolies G, Heck LW, Saway A, Blosch C, Hanna R, Koopman WJ. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
69. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch C. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
70. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Int Med 1999;130:478-86.
71. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Lange MS, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
72. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS. The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
73. Sands BE, Podolsky DK, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, DeWoody KL, Braakman TAJ, Woody JN. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC). Gastroenterology 1996;110:A1008.
74. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered anti-TNFα antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-5.
75. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. treatment of ulcerative colitis in the cottontop tamarin using antibody to tumor necrosis factor alpha. Gut 1997;40:628-33.
76. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rhematoid arthritis: nested case control study. Br Med J 1998;317:180-1.
77. Kristal AR, Nasca PC, Burnett WS, Mikl J. Changes in the epidemiology of non-Hodgkin's lymphoma associated with epidemic human immunodeficiency virus (HIV) infection. Am J Epidemiol 1988;128:711-18.
78. Greenstein AJ, Mullin GE, Strauchen JA, Heimann T, Janowitz HD, Aufses AH, Sachar DB. Lymphoma in inflammatory bowel disease. Cancer 1992;69:1119-21.
79. Loftus EV, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Risk of lymphoma in inflammatory bowel disease: a population-based estimate. Gastroenterology 1998;114:A1024.
80. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-19.
81. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, Hellers G. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994;107:1675-9.